Amgen Stock Signals Its Confidence. The Market Agrees.
The real bet is on what lies beyond this year's performance: a pipeline that could change everything.
YahooyesterdayMRK
How Did Merck Stock Beat The Market With Slowing Sales?
Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.
YahooyesterdayMRK
Beyond The Cloud Giants: What Could Power NVIDIA Stock From Here?
The market is obsessed with a handful of hyperscalers, but the real story might be the thousands of customers you've never heard of.
YahooyesterdayMRK
AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks
AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay invested.
Yahoo2 days agoMRK
Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?
Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster cardiometabolic franchise.
Yahoo2 days agoMRK
Global Health Leader Jeffrey L. Sturchio, PhD, Joins FINN Partners' Health Policy and Impact Group as Senior Advisor
FINN Partners, one of the world's largest independent communication, public affairs and marketing firms, today announced that Jeffrey L. Sturchio, PhD, is joining as a senior adviser. He will be part of FINN's Global Health Practice and work with the Health Policy and Impact Group. Dr. Sturchio's appointment strengthens a multinational team whose expertise spans health policy, stakeholder engagement, communications and purpose, adding one of global health's most respected advisors to its ranks.
Yahoo2 days agoMRK
Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
RAHWAY, N.J., September 02, 2026--Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
Yahoo2 days agoMRK
Did Merck’s (MRK) First Positive Phase 3 Individualized mRNA Cancer Trial Just Redefine Its Moat?
In August 2026, Merck & Co., Inc. and Moderna, Inc. reported that their Phase 3 INTerpath-001 trial of individualized mRNA therapy intismeran autogene plus KEYTRUDA in completely resected stage IIB–IV melanoma met its primary and key secondary endpoints, improving recurrence-free and distant metastasis-free survival versus KEYTRUDA alone with no new safety issues identified. This marks the first positive Phase 3 outcome for both an individualized neoantigen therapy and an mRNA-based cancer...
Yahoo2 days agoMRK
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.
Yahoo2 days agoMRK
Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III
GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real value of mRNA technology sits right now.
Yahoo2 days agoMRK
The Oral PCSK9 Inhibitor Market Enters High-Growth Phase Owing to the Approval of Merck's LIPFENDRA and the Emergence of Oral PCSK9 Inhibitor Drugs, Including, AstraZeneca's AZD0780, Aqur's AQR-008, and Others | DelveInsight
DelveInsight's PCSK9 Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Dyslipidemia, Hypercholesterolemia (Familial + Non-Familial), ASCVD, Coronary Revascularization (CABG and PCI), ACS (Acute Myocardial Infarction & Unstable Angina), and others. The selected indications are based on approved therapies and o
Yahoo3 days agoMRK
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
Yahoo3 days agoMRK
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Benzinga8 days agoMRK
Moderna Borrows $2 Billion To Expand Oncology Business
Moderna announces a $2 billion convertible senior note offering to fund its oncology business growth and strategically manage debt.
Benzinga8 days agoMRK
ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’
ARCT stock was most recently buoyed by positive late-stage results from Merck and Moderna on their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients.
Yahoo13 days agoMRK
3 American Stocks Showing the Same Setup That Sent Moderna Up 177%
Moderna's 130% day ran on five conditions. We screened the market for stocks like Moderna and found three names, none a biotech.
Yahoo13 days agoMRK
Moderna, Merck Cancer Vax Gives Hope
Scientists are on the cusp of fulfilling a decades-long quest: to use vaccines to teach the immune system to spot and destroy cancer cells. News that an mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. kept melanoma from returning in a large, late-stage trial marks a critical next chapter for a technology beleaguered by post-pandemic political backlash and years of false starts before then. Bloomberg Opinion Columnist Lisa Jarvis writes "Moderna and Merck's Cancer Vaccine Is a Marvel."
Yahoo13 days agoMRK
SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation
The stock has gained over 20% in the past five days, marking its best week since early July.
Yahoo13 days agoMRK
Moderna, Robinhood, Marvell, Tesla, SpaceX, and More Stocks That Explain Today’s Market
Moderna shares rise to close out a week of wild swings. Crypto stocks also extend their recent rally.
Yahoo13 days agoMRK
Merck (MRK) Gains A New Cancer Growth Story As Valuation Debate Heats Up
Merck (MRK) is back in focus after announcing that its personalized mRNA cancer vaccine, intismeran autogene, combined with Keytruda, achieved statistically significant gains in keeping high-risk melanoma from recurring or spreading in a Phase 3 trial. See our latest analysis for Merck. Merck’s recent mRNA melanoma result has arrived alongside powerful price momentum, with a 30 day share price return of 18.0% and a year to date share price return of 40.0%. The 1 year total shareholder return...
Yahoo13 days agoMRK
Thank Moderna for the Healthcare Sector’s Standout Week
It's been a good week for healthcare, with one stock's dramatic gains driving the sector higher. Moderna stock saw its best weekly performance ever, rising over 140%. The stock surged after the pharmaceutical giant announced promising results out of trials for its cancer vaccine.
Yahoo13 days agoMRK
Why Iovance Biotherapeutics Stock Hit 52-Week High
Iovance Biotherapeutics stock hits a 52-week high as investors weigh Moderna-Merck cancer data, Amtagvi sales and analyst price target hikes.
Benzinga15 days agoMRK
This Allstate Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Wall Street analysts changed outlook on top names. Check all rating changes, including upgrades/downgrades, on Benzinga analyst ratings page.
Benzinga15 days agoMRK
This Merck Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Wall Street analysts upgraded PGR, MRK, EPR and initiated coverage on BEKE and IONS. Check analyst ratings and price targets for these stocks.
Benzinga15 days agoMRK
Okta To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Benzinga15 days agoMRK
Merck And Moderna's Melanoma Results
Moderna and Merck have been running a large Phase III trial in over a thousand high-risk patients who had already had surgery to remove cutaneous melanoma tumors. Read more here...
SeekingAlpha15 days agoMRK
Which dow jones stocks are moving on Wednesday?
Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Wednesday.
ChartMill15 days agoMRK
These dow jones stocks are moving in today's session
Stay updated with the movements of the dow jones index in the middle of the day on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.
ChartMill15 days agoMRK
Merck Just Raised the Stakes for Pfizer's Cancer Vaccine Ambitions
Merck's deeper push into personalized cancer vaccines raises the competitive bar for Pfizer, BioNTech in biotech's fastest-growing race.
Benzinga16 days agoMRK
Pfizer Stock Rises Wednesday: What's Going On?
Pfizer Inc (NYSE:PFE) shares are trading higher Wednesday, moving in sympathy with mRNA cancer vaccine-related companies after Merck & Co Inc (NYSE:MRK) and Moderna Inc (NASDAQ:MRNA) announced that their combination therapy of intismeran autogene and Keytruda showed positive recurrence-free survival results in melanoma patients.
Benzinga16 days agoMRK
Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine
Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn’t always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across […]
Yahoo21 days agoMRK
Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress
Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to US$136.85. Analysts link these higher targets to research that highlights Merck’s pipeline progress, recent business development moves and continued focus on late stage therapeutics. As you read on, you will see how to track these moving pieces and what they could mean for the evolving Merck story in the coming years. Stay updated as the Fair Value for...
Yahoo21 days agoMRK
Merck (MRK) Stock Looks Fully Valued Following Raised Revenue Outlook
Merck stock has almost doubled investors' money over the past five years, yet there is a clear split between valuation tools. A Discounted Cash Flow (DCF) estimate points to a sizeable gap to intrinsic value, while market based multiples suggest the shares are already pricing in a lot of optimism. Merck has returned 99.7% over five years, which puts recent gains in focus as investors weigh how much future growth is already reflected in the price. Ongoing investment in oncology and new...
Yahoo21 days agoMRK
QUICK SPARK: Dell, JPMorgan, Merck All Mark New All-Time Highs
Dell, JPMorgan and Merck hit all-time highs on Thursday. Michael Dell's wealth surged, making him the fifth richest person globally.
Benzinga21 days agoMRK
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon
SeekingAlpha22 days agoMRK